Personalized Metabolic Analysis of Diseases by Cakmak, Ali & Celik, M. Hasan
 Personalized Metabolic Analysis of Diseases 
Ali Cakmak and M. Hasan Celik 
Abstract— The metabolic wiring of patient cells is altered drastically in many diseases, including cancer. Understanding the 
nature of such changes may pave the way for new therapeutic opportunities, as well as the development of personalized treatment 
strategies for patients. In this paper, we propose an algorithm, Metabolitics, which allows systems-level analysis of changes in 
the biochemical network of cells in disease states. It enables the study of a disease at both reaction- and pathway-level 
granularities for detailed and summarized view of disease etiology. Metabolitics employs flux variability analysis with an objective 
function which is dynamically built based on the biofluid metabolomics measurements in a personalized manner. Moreover, 
Metabolitics builds classification models for each disease to diagnose patients and predict their subgroups based on the computed 
metabolic network changes. We demonstrate the use of Metabolitics on three distinct diseases, namely, breast cancer, Crohn’s 
disease, and colorectal cancer. Our results show that the constructed supervised learning models successfully diagnose patients 
by f1-score of over 90% on the average. Besides, in addition to the confirmation of  previously reported breast cancer associated 
pathways, we discovered that Butanoate metabolism experiences significantly decreased activity, while Arginine and Proline 
Metabolism is subject to significant increase in activity, which have not been reported before. Metabolitics is made available as a 
Python package in pypi. 
Index Terms— Biomedical Informatics, Classification Algorithms, Optimization, Supervised Learning, Systems Biology  
——————————      —————————— 
1 INTRODUCTION
HE phenotype of diseases has often reflections on the 
metabolism of patients [18], [42], [1], [11], [20]. Certain 
pathways may be boosted, while some others may experi-
ence activity decrease. Collectively, such changes may ex-
plain the etiology of a disease [18], [44]. In this paper, we 
propose an algorithm, Metabolitics, which quantifies the 
changes in activity levels of pathways (and their reactions) 
given concentration fold changes for a set of metabolites. It 
later employs the computed metabolic activity changes as 
features to build classification models that accurately diag-
nose patients. 
A number of past studies (e.g., [13], [24], [56], [71], [77]) 
focused on pathway/reaction level analysis of high 
throughput biological data. The initial set of studies 
mainly employed pathway enrichment analysis ([56], [59], 
[68], [71], [72], [73], [74], [75], [76]). Briefly, these methods 
first identify significantly changing genes/metabolites in a 
given omics dataset. Then, the identified metabo-
lites/genes are mapped to the pathways that they partici-
pate. Based on the number of changing metabolites/genes 
included in each pathway, statistical significance analysis 
is performed to identify those pathways that are signifi-
cantly overrepresented with the measured genes or metab-
olites. Accordingly, each pathway is assigned a score based 
on the computed statistical test values. iOmicsPass [67] ex-
tends these approaches from node-level view to edge-level 
view in the context of the biological networks. More spe-
cifically, it does not consider the measured entities by 
themselves, but focuses on the direct interactions of the 
measured biological entities. To do this, it first computes 
co-expression scores for interactions based on their source 
and target entities’ Z-scores. Next, using the interaction 
scores, it computes the significantly differing subnetworks. 
Then, on these computed subnetworks, pathway enrich-
ment analysis is performed. XCMS Online [78] combines 
statistical significance-based filtering at both metabolite 
and pathway levels. The next set of methods ([13], [33], 
[50]) directly transfer the measured metabolite/gene 
changes to their corresponding pathways without any fil-
tering. Then, statistical significance analysis is done on the 
pathways and their change levels to assign them a deregu-
lation score. These methods consider each pathway as a 
collection of genes/metabolites, and ignore the interac-
tions between these entities. An extension of the above set 
of methods also considers pathway topology ([12], [28], 
[52], [54], [69]). More specifically, some measured 
genes/metabolites are given more weights in the statistical 
significance analysis based on the centrality of each 
gene/metabolite in the pathway network topology. To 
quantify the centrality, different measures may be em-
ployed, such as betweenness, Eigen vector centrality (e.g., 
PageRank), neighborhood size, etc. [27].  
The state of the art in this particular field is represented 
by Pathifier [13] and Paradigm [54]. Pathifier considers 
each pathway as a metabolite vector, matching the meas-
ured metabolites with the pathways that they participate. 
In this vector, each entry represents the concentration 
change measured for the metabolite corresponding to that 
vector row. Pathifier computes the principal curve that 
best fits the region where each individual is represented as 
a point in this high-dimensional space. On this curve, the 
mean distance from the points representing a person to the 
points representing healthy individuals is called pathway 
dysregulation score and shows how the pathway has 
changed in that individual. 
Paradigm [54] is another successful approach in path-
way-based analysis domain. It employs probabilistic 
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graph models to compute probability values for each path-
way. A pathway is turned into what is called a factor graph. 
A factor graph contains a set of nodes representing differ-
ent biological entities and their states. For instance, for 
each gene in a pathway, the factor graph contains the fol-
lowing nodes: gene, mRNA, protein, and active protein. 
The factor graph contains an edge for any kind of infor-
mation flow or state change between these nodes. For in-
stance, there is an edge from a gene to its mRNA represent-
ing transcription, an edge from mRNA to protein repre-
senting its translation, etc. Each node in a factor graph rep-
resents a variable which can only have one of following 
three discrete values: 1 (activation), 0 (normal), -1 (de-acti-
vation). The values of variables are learned from the pro-
vided omics data. 
None of the above summarized pathway analysis meth-
ods considers the fact that pathways are part of a large bio-
logical network, and they interact with each other. The main 
novelty of the proposed method in this paper is that we per-
form the analysis on the whole pathway network in a holis-
tic manner, rather than considering each pathway in an iso-
lated manner. The main advantage of such an approach is 
that, for a given disease, it allows to identify those key player 
pathways for which there may be few or no associated 
gene/metabolite measurements in the analyzed omics data. 
Our method is not specific to the metabolomics domain. It 
may be easily extended to be used for the analysis of other 
types of omics data (e.g., mRNA) as well.  
In brief, Metabolitics assigns a score for each path-
way/reaction in a patient. This score represents how much 
the activity of the corresponding pathway/reaction differs 
from that of healthy individuals (in a negative or positive 
way). In order to achieve this, Metabolitics works on the 
whole network of metabolic pathways. It turns the analysis 
task into an optimization problem [38] where the objective 
is dynamically set to maximize the flux for increasing me-
tabolites’ reactions, and minimize the flux for decreasing 
metabolites’ reactions in proportion to their fold changes. 
The metabolic network is assumed to be in steady state 
[35], that is, the amount of consumption and production is 
equal for all the metabolites. The steady state requirements 
are incorporated as constraints into the optimization prob-
lem. Then, the optimization problem is solved with linear 
programming [14]. Since the optimization problem is un-
der-determined [38], there are usually multiple solutions. 
In order to accommodate multiple solutions with a single 
score, we employ flux variability analysis [31] to identify 
the lower and upper bound flux values for each pathway. 
The average lower and upper flux values of healthy indi-
viduals are considered as reference values. Then, for each 
pathway, Metabolitics compute how much the lower and 
upper flux values differ from the reference values in a 
given patient. The average of the changes in upper and 
lower flux bounds of a pathway is assigned as the “diff” 
score of the pathway. In this study, Metabolitics works on 
Recon consensus human metabolic network dataset [53]. 
Once "diff" scores are computed, Metabolitics builds su-
pervised-learning models to automatically diagnose pa-
tients based on the computed metabolic changes. In partic-
ular, each individual is represented as a vector of the com-
puted personalized pathway diff scores. 
Fig. 1 illustrates a real life use-case scenario for Metab-
olitics. More specifically, first, some blood sample is col-
lected from an individual. Then, this sample is run through 
LC/MS process to identify the metabolites and their con-
centrations in the blood sample. Next, Metabolitics is run 
to identify the possible differentiations in the metabolic 
network of the individual. Then, using the pre-built classi-
fication models in its database, Metabolitics provides a 
physician with a set of likely diseases (if any) that the indi-
vidual may have. At this point, if needed, the physician 
may further request more specialized tests before finaliz-
ing the diagnosis. Once the individual is diagnosed with a 
disease, the physician may look at the details of the com-
puted metabolic changes in the individual. Accordingly, 
the root cause of the condition may be discovered, and an 
appropriate treatment strategy (e.g., a particular medicine, 
diet, etc.) may be planned by the physician in a personal-
ized manner. As an example, suppose that an individual 
has high cholesterol condition. There may be at least three 
different underlying causes for high cholesterol [17]: (i) 
cholesterol may be excessively absorbed in intestines, (ii) 
too much cholesterol may be produced in the cells, or (iii) 
there may be a slowdown in the conversion of excess cho-
lesterol to bile acids. For case (i), the physician may pre-
scribe Ezetimibe (which inhibits the uptake of cholesterol 
through intestines). For case (ii), the physician may pre-
scribe HMGCoA reductase inhibitor drugs which target 
endogenous cholesterol synthesis. On the other hand, for 
case (iii), there is no known medicine, and the only possible 
treatment strategy would be adopting a diet style which 
has no or low level of cholesterol. 
In order to evaluate the Metabolitics algorithm, we ap-
ply it on breast cancer, Crohn's disease, and colorectal can-
cer. We demonstrate that Metabolitics (i) captures biologi-
cally relevant information, (ii) accurately diagnoses pa-
tients using machine learning, (iii) is robust to decrease in 
the amount of measurement data, and (iv) provides more 
coverage and robustness to data loss than the state of the 
art. 
We have also implemented Metabolitics as a web-based 
Fig. 1. Big Picture – A use case scenario for Metabolitics 
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tool, MetaboliticsDB (online at http://metabolitics.bi-
odb.sehir.edu.tr), which is described in another work [7]. 
2 METHODS 
In this section, we present the details of the Metabolitics 
algorithm. We use Recon2 dataset [53] as the metabolic net-
work data. Recon2 is (genome-scale metabolic reconstruc-
tion) network model which includes 5324 metabolites and 
7785 reactions in the humans.  There are in total 100 path-
ways which are non-overlapping subgraphs of the net-
work; thus, each has a unique set of reactions. Although, 
Recon2 used in this study for metabolite name matching, 
flux variability analysis, and feature extraction, Metab-
olitics is generic enough to adapt other network models. 
In essence, the Metabolitics algorithm consists of the 
following steps.  
1. Matching the names of the metabolites in the input 
metabolomics data to the metabolites in our database,  
2. Dynamic creation of a linear programming model,  
3. Flux variability analysis,  
4. Calculation of reaction and pathway diff values,  
5. Statistical significance analysis,  
6. Feature extraction,  
7. Feature elimination,  
8. Building classification models for disease diagnosis  
2.1 Matching Metabolite Names 
It may not be possible to match all the metabolite names in 
a given metabolomics dataset to the metabolites in our da-
tabase [41]. The main reason for this is that many metabo-
lites do not have a standard common name used by all the 
researchers. Therefore, as a first step, one needs to find the 
equivalents of user-provided metabolites in our database. 
In this study, we compiled the set of all known alternative 
names for each metabolite by cross-integration of different 
metabolite data sources. More specifically, we combined 
the names of the metabolites that are included in two 
widely used, publicly available data sources, HMDB [58] 
and CheBI [23]. During this integration process, we consid-
ered two metabolite entries, one from HMDB and one from 
CheBI, as the same, if they share at least one synonym. 
Next, we search for each metabolite in our database in this 
combined name dataset, and transferred all known syno-
nyms to our database for each matching record. Finally, we 
attempt to match the names in the metabolomics dataset 
given as input to the synonyms stored in the database.  
2.2 Dynamically Constructing Linear 
Programming Models in a Personalized 
Manner 
Metabolic analysis studies in the literature generally as-
sume that metabolic networks are in steady state [30], [34]. 
The steady state hypothesis basically assumes that the total 
production of each metabolite in the metabolic network 
equals to its total consumption. This allows metabolic net-
works to be expressed mathematically as a set of linear 
equations. More specifically, a metabolic network can be 
expressed as a matrix in which the rows correspond to the 
metabolites and the columns correspond to the reactions in 
the network. In this matrix, a cell located at row i and col-
umn j contains the stoichiometry of metabolite mi in reac-
tion rj. If metabolite mi does not participate in reaction rj, 
then 0 is placed in the corresponding cell. With this repre-
sentation, flux balance analysis can be expressed as linear 
program under the steady state assumption as follows [38]: 
𝑚𝑎𝑥𝑖𝑚𝑖𝑧𝑒 𝐶𝑇 ×  𝑉 
    𝑠𝑢𝑏𝑗𝑒𝑐𝑡 𝑡𝑜 𝑆 ×  𝑉 =  0 𝑎𝑛𝑑 𝑣𝑙𝑜𝑤𝑒𝑟 <  𝑉 <  𝑣𝑢𝑝𝑝𝑒𝑟       (1) 
 
In the above equation, S is the matrix representation of the 
metabolic network, V is a vector of variables which repre-
sent reaction fluxes, C is coefficient of reactions, vlower and 
vupper is the upper and lower boundary of the reactions' flux 
values. By solving the above linear program, the values of 
reaction flux variables in vector V are determined. At this 
point, the steady state assumption is represented as con-
straints. In single cell organisms, the objective function is of-
ten set to maximize the fluxes of reactions that produce cell 
building blocks (amino acids, nucleotides, lipids, etc.) to am-
plify the cell biomass. However, for multi-cellular organ-
isms, e.g., humans, there is no agreed-upon standard for the 
objective function structure. In this study, the objective func-
tion is dynamically set in a personalized manner. That is, the 
objective function (i.e., 𝐶𝑇 ×  𝑉) is constructed as follows. 𝑉 
includes flux variables for all reactions that produce at least 
one metabolite in the input metabolomics dataset. The cor-
responding reaction flux coefficients in 𝐶 are designated as 
specified in equation (2).  
 
            𝐶𝑅 =    ∑ 𝑚𝑓𝑐  𝑆𝑚,𝑅 / 𝑆𝑚
𝑡𝑜𝑡𝑎𝑙
𝑚 𝜖 𝑀𝑅                                    (2) 
 
𝑆𝑚
𝑡𝑜𝑡𝑎𝑙 =    ∑  𝑆𝑚,𝑟𝑟 𝜖 𝑅    
where  
 CR is the coefficient of a reaction R's flux variable, 
 MR is the set of metabolites that are produced by R, 
 mfc is the measured fold change for metabolite m, 
 Sm,R is the stoichiometry of metabolite m in R, 
 𝑆𝑚
𝑡𝑜𝑡𝑎𝑙 is the total stoichiometry of m over all pro-
ducer reactions of m in the metabolic network. 
The objective function is heuristically built based on the in-
tuition that, by incorporating mfc as a coefficient, our aim is 
to make sure that the higher the change in the measured 
concentration of a metabolite, the more effect it will have 
on the objective function value. In doing so, the total stoi-
chiometry of the metabolite is used as a normalization term 
to prevent the popular (currency) metabolites from artifi-
cially dominating the objective function. This is because, in 
the metabolic network, there are some hub (currency) me-
tabolites which contribute in many reactions. H2O, ATP, 
and NAD are some of the examples. Many studies [64] re-
move those metabolites from their analysis, but the re-
moval of the currency metabolites may damage the stoichi-
ometric balance of the metabolic network. Moreover, the 
removal of the currency metabolites is a strong assump-
tion; therefore, should be avoided.  In order to accommo-
date the above considerations, we keep the currency me-
tabolites, and normalize each metabolite with its total stoi-
chiometry. Moreover, the objective function is defined 
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completely based on the measured metabolite concentra-
tion changes which will be different for each person. This 
way of modeling allows our approach to produce person-
specific results. Besides, metabolite concentrations need to 
be normalized as fold-changes since the scale of each me-
tabolite is different than each other, and a change is only 
meaningful when compared to reference healthy value. 
That is, 
 
            𝑚𝑖
𝑓𝑜𝑙𝑑𝐶ℎ𝑎𝑛𝑔𝑒
= log 𝑚𝑖
𝑐 − log 𝜇𝑚
ℎ𝑒𝑎𝑙𝑡ℎ𝑦
                            (3) 
where 
 𝑚𝑖
𝑐 is the concentration measurement of metabolite m 
in individual i. 
 𝑚𝑖
𝑓𝑜𝑙𝑑𝐶ℎ𝑎𝑛𝑔𝑒
 is the concentration fold change of metab-
olite m in individual i 
 𝜇𝑚
ℎ𝑒𝑎𝑙𝑡ℎ𝑦
 is the mean concentration of metabolite m in 
all healthy individuals. 
In order to compute the fold-changes as in eq. 3, we first 
compute the reference mean concentration of each metab-
olite based on the measurements in healthy individuals. 
Then, for all individuals (including healthy individuals 
and patients), we compute the metabolite fold changes rel-
ative to the above computed mean values. As a result, 
though usually smaller than patients, even healthy indi-
viduals are assigned metabolite fold changes. These fold 
changes are employed for each individual in the corre-
sponding objective function as described above. We use 
this the objective function in flux variability analysis. 
2.3 Flux Variability Analysis 
Typically, the number of metabolic reactions is greater 
than the number of metabolites in a metabolic network 
[38]. Hence, the optimization problem presented in the 
previous section is underdetermined. Therefore, many al-
ternative solutions (i.e., reaction flux value assignment) are 
usually possible. Each of these alternative solutions may 
allow the cells to achieve different goals. In order to cover 
all of these alternative solutions, flux variability analysis 
(FVA) [36] is employed. FVA allows to determine the min-
imum and maximum flux values for each reaction. In brief, 
FVA works as follows. First, the value of the objective func-
tion is determined by solving the optimization problem de-
scribed in the previous section. Then, the value of the objec-
tive function, computed in the previous step, is added to the 
model as an additional constraint. For each reaction R in the 
metabolic network, the objective function is set to maximize 
the flux of R, and the optimization problem is solved. The 
computed objective function value is stored as the upper 
boundary for the flux of R. Next, the objective function is set 
to minimize the flux of R, and the optimization problem is 
solved. The computed objective function value is stored as 
the lower boundary for the flux of R. This process is re-
peated for each reaction in the metabolic network. 
2.4 Diff Value Computation 
Pathways are defined by biologists as a set of closely re-
lated reactions that work together, often in a particular or-
der, to achieve a common cellular goal (e.g., fatty acid syn-
thesis). Analyzing the perturbations caused by diseases in 
metabolic networks in terms of changes in known path-
ways is a commonly used summarization method [13], 
[26]. In this study, we adopt a similar approach as well. To 
this end, for each pathway, we compute a "diff" value that 
represents the differentiation of the pathway activity for an 
individual in reference to healthy individuals. Pathway 
diff values are computed as follows. 
First, the average lower and upper flux boundary values 
for each reaction is computed as described above based on 
the metabolomics data obtained from healthy individuals. 
These values are recorded as “reference” values. Then, dur-
ing the analysis of a given set of metabolomics data of an 
individual, the difference between the lower and upper flux 
values obtained from this data set and the reference values 
are computed and recorded for each reaction as its “diff 
value”. Then, for each pathway, its diff value is computed 
as the mean diff value of its reactions. This is similar to path-
way-level aggregation enrichment methods [62] in the lit-
erature. As an alternative to computing the mean for all re-
actions, we also consider the mean of top-k reactions with 
the highest ANOVA score. A diff value may be negative or 
positive. Negative values indicate that the corresponding 
pathway/reaction is less active by the diff amount, while 
positive values indicate that the pathway experiences an ac-
tivity increase with respect to healthy people. 
2.5 Statistical Significance Analysis 
It may be misleading to directly interpret a diff value solely 
based on its magnitude. In this study, we perform a statis-
tical significance analysis to evaluate the possibility of ran-
dom occurrence of these scores. To this end, ANOVA [9] is 
used to calculate the F- and p-values (corrected for multi-
ple hypothesis testing using Benjamini-Hochberg), which 
indicate the statistical significance of pathway activity dif-
ferences between patient and healthy groups. We prefer 
ANOVA because it is widely used in bioinformatics stud-
ies [61]. This way, the essential pathway changes that char-
acterize a disease may be statistically determined. Such 
pathways may be focused to select the most appropriate 
treatment from existing therapies for personalized medi-
cine, and for new drug target discovery. 
2.6 Machine Learning-based Classification 
Analysis results of metabolomics data from known (i.e., la-
beled) healthy individuals and patients are used as train-
ing data to build machine learning-based classification 
Flux variability analysis [63]: 
    where solveFBA returns CT V 
    input: FBA problem as P 
    output: minimum and maximum feasible flux for each 
reaction of FBA problem as Rmax and Rmin 
  
     solution = solveFBA(P) with current objective 
     P also subject to CT V = solution  
 
     for each r in P.reactions do 
          set maximization of r as a new objective 
          Rmaxr= solveFBA(P) 
 
           set minimization of r as a new objective 
           Rminr= solveFBA(P) 
 
     return Rmax, Rmin 
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models. These trained models are then employed to pre-
dict whether a given metabolomics analysis results belong 
to a patient or a healthy person. In this context, each anal-
ysis result should first be transformed and represented as 
a numerical vector. To this end, one needs to first deter-
mine the structure and content of these numeric vectors. 
Feature Extraction: Since our approach in this study is 
pathway-based, pathway diff values are used as features 
(i.e., entries in the numeric vector representation). There 
are 100 different pathways in the current version of the 
Recon data. Hence, in this study, the size of each vector 
representing an individual is 100. 
Feature Selection: The employed features may be cor-
related among themselves, which may negatively affect 
the performance of the trained classification models. In or-
der to alleviate this problem, as a preprocessing step, we 
eliminate the highly correlated features from the vector 
representation before building a classification model. We 
consider recursive feature elimination [22], feature im-
portance based on feature weights, and ANOVA-based 
feature selection. 
Dimensionality Reduction: We further perform di-
mensionality reduction. To this end, we consider the Prin-
cipal Component Analysis [3], factor analysis [65], and 
Truncated SVD methods. 
Classification: A classification model for a disease is 
constructed by using the vector representations of the 
metabolomics analysis results from healthy individuals 
and patients as training data. To this end, there are a num-
ber of alternative methods available in the literature. 
Among the most commonly used algorithms are Support 
Vector Machines [22], Decision Trees [29], and Logistic Re-
gression [6]. In this study, we considered several classifica-
tion methods, and employed Logistic Regression, as it pro-
vides the best or comparable performance.  Repeated (10 
times) stratified K-fold cross-validation is performed to 
test the performance of alternative machine learning meth-
ods. In each iteration, 8 folds are used for training, 1 fold is 
used for parameter tuning, and 1 fold is used for testing. In 
each repeat, the data is re-shuffled and re-splitted to k-fold. 
Reported results are average and standard deviation of the 
100 folds (k=10, repeats=10). 
3 EXPERIMENTAL EVALUATION 
In this section, we present results from an experimental 
evaluation of Metabolitics on a breast cancer dataset [26] 
that includes around 160 metabolite measurements col-
lected from 214 individuals’ plasma samples (76 healthy 
individuals and 138 breast cancer patients). We also apply 
Metabolitics on Crohn’s disease and colorectal cancer for 
further evaluation. We first present evaluation on breast 
cancer dataset in detail, and later discuss the results on 
Crohn's disease and colorectal cancer datasets. 
The implementation of the presented algorithms are 
done in Python. ScikitLearn [39] library was used for ma-
chine learning models and statistical significance analysis. 
Cameo [14] library was used for FVA calculations. 
3.1 Evaluation of Pipeline steps of Metabolitics 
We benchmark each step of the pipeline in comparison to 
alternative approaches to justify our choice of algorithm in 
each pipeline step. 
Pipeline steps until flux variable analysis are fixed in 
the Metabolitics. The remaining steps (such as feature se-
lection, dimensionality reduction, etc.) are optional, and 
may be easily plugged-in (or out) using Metabolitics API. 
We compare the f1-score of each step that follows flux var-
iable analysis with repeated stratified K-fold (10 fold and 
10 repeat) cross-validation on breast cancer dataset. Re-
sults are reported in Figure 2. Higher classification perfor-
mance achieved using reaction-level diff-scores. However, 
reaction level information alone is not interpretable due to 
a huge number of reactions (about 7500 of them). Thus, we 
aim to obtain pathway level score which achieves similar 
classification performance.  
Averaging all reaction scores to obtain pathway scores 
slightly lowers scores because few number of reactions for 
each pathway is significantly altered and probably have 
important signal unlike the rest of the reactions whose 
change is insignificant. Thus, we choose top-k significant 
reactions (k=100) based on their ANOVA score, and then 
compute the average pathway diff score over top-k reac-
tions. Tuning the number of those top-k reactions does not 
make much difference; thus, we use k=100 for this 
study.  Reaction-level feature selection slightly decrease 
the performance. However, averaging to pathway-level 
slightly improve the performance of classification back to 
the same level. Feature selection at pathway-level contrib-
utes to the pathway-level performance, as it better repre-
sents pathway alteration characteristics. We have consid-
ered recursive feature elimination (89.8 ± 4.8) [22] and fea-
ture importance based on feature weights (89.4 ± 4.5) in lo-
gistics regression as alternatives to ANOVA. However, 
none of them provides better performance than ANOVA; 
thus, we employ and report ANOVA in feature selection. 
 
PCA 
Metabolitics produces pathway scores as output. Meta-
bolic pathways are beneficial for biological interpretation, 
but they may not describe the latent space of the metabolic 
Fig. 2. Repeated stratified K-fold (10 fold and 10 repeat) cross-valida-
tion on breast cancer dataset (Feature selection is ANOVA-based). 
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network. For instance, some increased activity in one en-
ergy-related pathway is probably associated with a change 
in another energy-related pathway. This phenomenon is 
also seen in the breast cancer dataset.  Figure 3 shows the 
variance of pathway score explained by PCA components. 
They clearly demonstrate that a few components of PCA 
explain most of the variance in pathway scores.   The first 
component of the PCA explains ~47% of the variance, and 
the first ten components explain ~95% of the variance. Alt-
hough there are 100 pathways in the metabolic network, 24 
components of the PCA explains all the variance. Be-
sides, Figure 4 visualizes the same dataset based on the 
first two components of the PCA, and there is a clear sepa-
ration between healthy and breast cancer samples. Thus, 
we employ PCA for the classification task, and ANOVA-
based feature importance scores of pathways for biological 
interpretation. Based on Figure 2, both methods are 
slightly better than raw pathway score. Moreover, there is 
no clear difference between PCA and reaction-level 
ANOVA-based feature selection. Moreover, we employ al-
ternative dimension reduction methods such as factor 
analysis (82.4 ± 1) [65] and Truncated SVD (89.7 ± 4.4) [66], 
but they do not have better performance than PCA. More-
over, PCA is not a default part of the Metabolitics.  It is 
only used in machine learning-related tasks due to faster 
training time. Pathway significance scores discussed in the 
paper are calculated without PCA using ANOVA, as this 
is a more likely scenario for most of the users who need 
enriched pathways for interpretation. 
 
Classifiers 
We also consider alternative classifiers. Average and 
standard deviation of f1-scores for each classifier, which 
are calculated with repeated-stratified K-fold (10 fold and 
10 repeat) cross-validation are presented in Figure 5. We 
tune hyper-parameters of each model, such as regulariza-
tion parameter and different regularization metrics  (L1 
and L2) for logistics regression and SVM, gini and entropy 
as criterion metric and different tree depths for decision 
tree and random-forest, different numbers of estimators 
for ensemble methods (adaboost and random-forest), etc. 
Although most of the performance figures are within the 
error bars of the alternative methods, logistic regression 
and linear-svm show higher performance than others. In 
this study, a simpler model such as logistic regression is 
employed due to two main reasons. Firstly, available data 
is relatively small (214 breast cancer, 40 Crohn's disease, 
114 Colorectal Cancer samples). Thus, training more recent 
complex models, such as deep neural networks, will likely 
overfit the data and not generalize.  Moreover, we demon-
strate that the performance of classification is not due to 
the learning capability or the complexity of the machine 
learning model, but the proposed subsystem analysis. 
3.2 Metabolitics Captures Biologically Relevant 
Information in Breast Cancer 
Table 1 lists the top-10 significantly changing pathways in 
breast cancer patients with their diff scores. Negative 
scores indicate that the average pathway flux decreases, 
and positive scores mean that the average pathway flux in-
creases, in comparison to the healthy individuals. Fig. 6 
Fig. 4. The separation healthy and breast cancer samples with two 
PCA components 
Fig. 3. The variance of pathway score explained by PCA components Fig. 5. f1-scores for different classification algorithms 
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shows the heatmap of the pathway diff values. 
In Alanine and Aspartate Metabolism pathway, the reac-
tion that experiences most flux increase is asparagine synthase 
(encoded by ASNS). This reaction converts glutamine into 
glutamate and asparagine. Glutamate is a precursor that leads 
to the biosynthesis of other amino acids which are needed 
by breast cancer tumor cells to proliferate [57]. 
The association of Arginine and Proline Metabolism with 
breast cancer is reported for the first time in this study. De In-
geniis et al. [10] suggested that NADP+, which is produced 
during the synthesis of proline from arginine, may be directed 
to PP-ribose-P synthesis. PP-ribose-P is later metabolized in nu-
cleotide synthesis. Breast cancer tumors may also be using the 
same mechanism to enhance nucleotide synthesis. 
Methionine and cysteine metabolism has the highest rate 
of increase in reaction NADPH: CoA-glutathione oxidoreductase 
(EC: 1.8.1.10). Breast cancer cells often experience high oxida-
tive stress [4]. Through the conversion of glutathione (GSH) to 
its oxidized form, glutathione disulfide (GSSH), ROS are neu-
tralized. Then, glutathione reductase converts GSSH back to 
GSH to process more ROS agents. Earlier studies (e.g., [40]) 
also report the increase of GSH and glutathione reductase activ-
ity in breast cancer tumors.     
Similarly, hypotaurine also has a significant effect on the re-
active oxidative stress states of cells [5], [19]. 
As related to the above phenomena, the CoA catabolism 
pathway exhibits a positive flux change. Acetate is an im-
portant input for lipid synthesis in breast cancer tumors [46]. 
More specifically, Acetyl CoA is first produced from Acetate 
(ACOT12) and then converted to Malonyl CoA (ACC-alpha) 
[47]. Malonyl CoA is the primary input metabolite in the first 
steps of fatty acid synthesis. 
In Table 1, the activity of Fatty Acid Oxidation significantly 
reduces while the activity of the Fatty Acid Synthesis (not 
among top-10 pathways) increases significantly (p-val < 0.01). 
Fatty acids are used for lipid synthesis, and lipids form the 
main structure of the cell membrane. In order to form new tu-
mor cells, lipids have a vital role as a building block of cell 
membranes [2]. Therefore, fatty acid synthesis is increased in 
tumor cells, and fatty acid oxidation is reduced. 
NTPs and dNTPs form the main input metabolites of nu-
cleotide synthesis. Nucleotide interconversion performs the 
transformations (d) NMP ↔ (d) NDP ↔ (d) NTP by transfer-
ring phosphate to produce the essential metabolites necessary 
for nucleotide metabolism. The increased activity of this 
pathway also indicates that the nucleotide synthesis in 
breast cancer tumor cells increases [48]. 
Eicosanoids are divided into 3 different subgroups: pros-
tanoids (COX), lipoxygenases (LOX), and ω-hydroxylases/epoxy-
genases. COX and LOX eicosanoids have a supporting role in 
breast cancer development and metastasis [55]. COXs are 
more active in ER-positive breast cancer tumors, while LOX's 
are more effective in ER-negative tumors. In the ER-positive 
breast cancer type, tumor cells have estrogen sensitive recep-
tors. Such tumors bind to the estrogen hormone, and estrogen 
accelerates the development and spread of these cells. COXs 
boost estrogen synthesis by increasing the activity of the rate 
limiting enzyme in estrogen synthesis, aromatase, and thus 
contribute to the development of ER-positive tumors [55].  
Even though Eicosanoid metabolism seems to have a nega-
tive diff value in Table 1, when we examine diff values for 
the individual reactions of this pathway, we observe that the 
activity of reactions producing COX type eicosanoids has in-
creased, and the flux value reactions producing other eico-
sanoid species has generally decreased. Since the number of 
reactions involved in the metabolism of non-COX eico-
sanoids was greater, the mean pathway differentiation value 
also comes out as negative. Based on the above observation, 
one may conclude that the majority of the breast cancer sub-
jects included in the analyzed dataset belongs to the ER-pos-
itive subtype.  
Butanoate is an important metabolite that has a therapeu-
tic effect against breast cancer by directing the cells to apop-
tosis and stopping cell growth [51]. Therefore, the activity of 
Butanoate metabolism in patients is lower than healthy peo-
ple. 
Finally, the increase in Glycolysis points to what is known 
as Warburg Effect [43]. That is, tumor cells consume and con-
vert glucose into lactate even though plenty of oxygen is 
available, and mitochondrial oxidation is possible. 
3.3 Metabolitics Accurately Diagnoses Breast 
Fig. 6. Heatmap for the significantly changing top-10 pathways in 
breast cancer. Subjects are placed on x axis. Each cell is colored 
based on the diff values for the corresponding pathway. 
Table 1. Significantly changing pathways in breast cancer with their diff 
scores computed by Metabolitics. The statistical significance values 
(i.e., F-val and p-val) are computed through ANOVA analysis based on 
computed diff values. The last column reports the measured metabolite 
counts for the reported pathways. Columns 5-6 provides the scores 
computed by Pathifier and Paradigm (discussed in Sec. 3.4) 
Pathway F-val p-val diff Pathifier Paradigm 
Met
Cnt 
Alanine and aspartate 
metabolism 
200 1.70E-31 1300 0.16 0.0012 7 
Arginine and Proline 
metabolism 
160 1.90E-26 850 0.46 -0.0190 8 
Methionine and cysteine 
met. 
130 2.50E-23 170 0.17 0.0240 6 
Taurine and hypotaurine 
met. 
130 1.00E-22 970 - 0.1800 1 
CoA catabolism 120 2.50E-22 610 - - 0 
Fatty acid oxidation 120 2.40E-21 -1100 0.21 - 15 
Nucleotide interconversion 110 2.70E-20 1300 - - 1 
Eicosanoid met. 80 6.30E-16 -730 0.50 - 4 
Butanoate met. 69 3.40E-14 -670 - - 0 
Glycolysis 68 4.60E-14 770 0.11 -0.0190 5 
Std. Deviation 883.5 0.17 0.0800  
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Cancer Cases 
We next demonstrate that Metabolitics allows to differentiate 
between healthy individuals and patients with high perfor-
mance. In brief, we build a machine learning classification 
model based on the pathway diff score profile of each subject 
in our dataset as described in Methods section. In order to 
evaluate the validity of the classification model, we perform 
repeated stratified K-fold (10 fold and 10 repeat) [15]. We 
obtained the f1-score with the Logistic Regression [25] (C = 
0.3e-6) algorithm as 89.9 ± 4.4. 
3.4 Comparison with the State of the Art  
We compare metabolitics with Pathifier [13] and Paradigm 
[54] in terms of (i) accuracy (AUC-ROC), (ii) coverage of 
the metabolism, and (iii) robustness to data loss.  
Accuracy 
Figure 7 presents AUC (Area under the Curve) ROC (Re-
ceiver Operating Characteristics) curve that is obtained 
with repeated stratified K-fold (10 folds and 10 repeats) 
cross validation. We use the default parameters of Pathifier 
and Paradigm, since they provide the best performance. 
Metabolitics has better AUC value than Paradigm [13]. 
Pathifier [53] seems to perform better than Metabolitics. 
However, these figures are misleading, as Pathifier and Par-
adigm overfit the data. More specifically, unlike Metabolitics, 
neither Paradigm nor Pathifier provides a programmatic API 
to split the train and test sets. That is, they learn and fit their 
model parameters on all the data. Paradigm scales the entire 
dataset. Thus, it also learns the mean of test dataset. Like-
wise, Pathifier employs the labels of the entire dataset to 
learn and extract pathway features. Thus, label infor-
mation is also embedded into a generated feature which 
leads to the critical overfitting problem. Paradigm is pro-
prietary software. Therefore, it is not available as open-
source, and we had to use the binary executable of Para-
digm to perform the comparison experiments in this study. 
Although Pathifier is available as open-source, its algo-
rithm does not lend itself well for using in a cross-valida-
tion setting with different training and test datasets. The 
primary reason for this is that Pathifier is not originally de-
signed with classification task in mind. Having said this, 
we have attempted to change the source code of the Pathi-
fier, but we ended up with an algorithm that is signifi-
cantly different than and may not be comparable to the 
original one.  Thus, we aborted this option, and employed 
the original algorithms in our experiments despite the 
known overfitting problem.  
To sum up, although Metabolitics cannot be compared 
with Paradigm and Pathifier in fair terms, it has compara-
ble performance. Moreover, we provide a programmatic 
API to separate train-test data for our users to avoid the 
overfitting issue of state of the art algorithms. 
Coverage of the Metabolic Network 
In this section, we demonstrate that Metabolitics provides 
higher coverage of the metabolism than Paradigm and 
Pathifier. The coverage of the metabolic network is im-
portant to discover the complete set of metabolic changes 
caused by a disease.  
According to Table 1, 4 of the 10 significant pathways re-
ported by Metabolitics cannot be detected by Pathifier (i.e., no 
dysregulation score is computed). Similarly, Paradigm misses 
5 of the top-10 pathways. The reason for this drawback of 
Pathifier and Paradigm is explained by the last column of Ta-
ble 1. That is, Pathifier and Paradigm are only capable of eval-
uating and scoring pathways with at least a few metabolites 
included in the analyzed metabolomics data set. Therefore, it 
may miss many important key pathways for which no meas-
ured metabolite is available in the analyzed metabolomics da-
taset. On the other hand, since Metabolitics considers the met-
abolic network as a whole, and the pathways are intercon-
nected in this network, it can produce analysis results about 
pathways for which no or few measurements are available.  
Robustness to Data Loss 
In this section, we compare the “robustness” of Metabolitics 
to that of Pathifier and Paradigm algorithms. We informally 
define the robustness as the resistance of an algorithm’s per-
formance to keep its initial value in the face of decrease in the 
number of measured metabolites. In other words, more ro-
bust algorithms experience lower performance loss, when the 
number of measured metabolites is less. In order to simulate 
the worst-case scenario, we first perform ANOVA to identify 
the most significantly differing metabolites between healthy 
individuals and patients. Next, we sort the metabolites by 
their F-values (as computed by ANOVA). Then, in an itera-
tive way, we systematically remove the top-10 metabolites 
with the highest F-values from the metabolomics dataset, and 
then rebuild the classification models in each iteration on the 
reduced dataset. Fig. 8 charts the average f1-score of stratified 
K-fold (K=10) cross validation for Metabolitics, Pathifier, and 
Paradigm after each metabolite removal iteration. As shown, 
Metabolitics is more robust to decrease in measured data than 
Pathifier and Paradigm, since it provides insights on parts of 
Fig. 7. AUC – ROC curve for Metabolitics, Pathifier, and Paradigm 
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the metabolic network with no metabolite measurements.  
3.5 Pathway Significance-based Prediction 
In this section, as an alternative method, we compute a 
pathway-wise significance that considers all positive and 
negative diffs in a pathway to determine whether the path-
way is indeed up- or downregulated (similarly to gene set 
enrichment analysis, e.g., [60]). Fisher exact test is used to 
calculate pathway-wise significance. More specifically, av-
erage of healthy and patient samples are computed sepa-
rately. As a result, for each pathway, we obtain two reac-
tion vectors, one for healthy and one for cancer patients. 
Then, Fisher exact test is performed for each pathway 
based on these reaction vectors. Contingency table matrix 
has “healthy” and “patient” as columns, and the numbers 
of increasing, decreasing, and unchanged reactions as 
rows, respectively. The resulting significance values are 
employed as features in the classification task. The f1-score 
of this classification is 80%, which is lower than the original 
Metabolitics approach. The lower f1-score of the signifi-
cance-based approach may be attributed to the following: 
(i) First, this approach only considers the direction of 
change in reaction fluxes (as either increasing or decreas-
ing), and ignores the magnitude of change. (ii) Second, this 
approach just focuses on the number of reactions that in-
crease or decrease, and does not consider the identity of 
these reactions, which leads to loss of information.  
3.6 Stability Analysis 
In this section, we further evaluate the stability of Metabolitics 
under systematically introduced noise in input data. The ma-
jor goal of this analysis is to test whether Metabolitics ampli-
fies the noise (introduced in the input metabolomics dataset) 
in its output diff scores. More specifically, in this analysis, 
some uniform noise between certain negative and positive 
range with increasing amount is added to input dataset to ob-
serve the effect of noise in the output of Metabolitics. Cosine 
distance is used to calculate the distance between the original 
and noise-added values in both input dataset and the corre-
sponding Metabolitics-generated output. Randomly gener-
ated 100 samples are used as reference values, and their input 
and output values are averaged each time before the calcula-
tion of distance. This experiment is repeated 100 times for 
each noise interval and the results are averaged and pre-
sented Figure 9. All the experiments are run on E. Coli net-
work to get results in a faster way, as a large numbers of runs 
are performed. Fig. 9 shows that the noise in the output grows 
slower than the rate of increase in the input noise. Thus, we 
conclude that Metabolitics does not amplify the noise or act 
unstable under noise.  
Moreover, we further performed another experiment to 
measure the effect of noise in metabolomics measurements on 
f1-score in breast cancer dataset. In this experiment, uniform 
noises proportional to metabolite fold-changes are added 
with increasing amounts, and Metabolitics analysis is per-
formed for each interval. Fig. 10 charts the change of f1-score 
as the noise amount increases. The graph shows that Metab-
olitics performs reasonably well under increasing noise 
amount as shown by the classification f1-score results.  
3.7 Applying Metabolitics on other Diseases 
In this section, to further validate the proposed methodol-
ogy, we demonstrate the application of Metabolitics on 
two additional disease datasets, namely, Crohn’s Disease 
[49] and Colorectal Cancer [45]. Fig. 11 presents the overall 
f1-score of Metabolitics in diagnosing different diseases. 
Crohn’s Disease (CD) is an autoimmune disorder that 
causes inflammation in the gastroenterological track of the 
patients. We run Metabolitics on a recent dataset [49] that 
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is obtained from the serum measurements of 40 subjects 
(20 with CD and 20 healthy). With the Metabolitics as-
signed pathway diff scores as features, a Logistic Regres-
sion-based classifier (with C = 0.3e-6) differentiated sub-
jects with CD from healthy ones with a mean f1-score of 
88% (over 10-fold cross validation). 
Colorectal Cancer (CRC) originates from the epithelial 
cells of colon or rectum, and it is one of the most common 
cancers. We run Metabolitics on a metabolomics dataset 
[45] that are obtained from Visceral Fat tissues of 55 sub-
jects (49 CRC patients, 6 healthy control). On this dataset, 
Logistic regression achieves 89% f1-score on classifying 
CRC patients and healthy samples.  
3.8 Sparsity Robustness Analysis 
In this section, we perform a simulation study to analyze the 
effect of sparsity in terms of the coverage of metabolomics 
measurements of the metabolic network over the stability of 
Metabolitics analysis results. The major challenge in this ex-
periment is the generation of metabolomics data that is as 
much realistic as possible, and covers the whole network. As 
a baseline approach, we ignored the network relationship be-
tween metabolites and assumed that all metabolites are inde-
pendent of each other. More specifically, we generate a ran-
dom metabolomics dataset which has full coverage of the net-
work by assuming normal distribution with a mean of 0 and 
a standard deviation of 1. To perform the simulation, we sys-
tematically decreased the network coverage by 5% by ran-
domly removing metabolites from the initial dataset at each 
iteration. At each step, we ran Metabolitics on the current data 
set, and compute the correlation between the current results 
and that of full coverage dataset. The results are presented in 
Fig. 12. The correlation decreases proportionally to the cover-
age reduction, and Metabolitics underperforms in this analy-
sis. This may be attributable to the unrealistic metabolomics 
data generation approach employed in this baseline run, as it 
unrealistically assumes that the concentrations of metabolites 
are independent from each other.  
Next, as a more realistic approach, we generated a new 
metabolomics data set by using the original breast cancer 
data set as a seed, and expanded it into a full coverage 
metabolomics data set as follows: For each unmeasured 
metabolite m, within the seed metabolomics data, we iden-
tified the metabolite that is most similar to m in terms of 
the reactions that it participates. That is, given two metab-
olites, we use the number of common reactions that they 
both participate as a proxy to their similarity. Assume that 
the most similar metabolite for m is x. Then, we assign the 
fold change of m as that of x plus a certain noise which is 
generated randomly with a normal distribution with a 
mean of 0 and a standard deviation of 0.1. Then, the same 
procedure as in the previous simulation is repeated. Re-
sults are shown in Fig. 13.  The figure shows that even with 
very sparse measurements, Metabolitics can provide 
highly correlated results with full coverage. 
4 DISCUSSION 
Through the analysis of a breast cancer, Crohn's disease, and 
colorectal cancer metabolomics data, we show that Metab-
olitics makes biologically relevant discoveries as supported 
by the literature. The assigned diff scores are consistent with 
the currently known understanding of breast cancer. What is 
more, we also discovered two breast cancer associated path-
ways, namely, Butanoate metabolism (significant decrease in 
activity), Arginine and Proline Metabolism (significant in-
crease in activity), which have not been reported before in the 
literature. 
Besides, Metabolitics-assigned diff scores allow to distin-
guish breast cancer patients from healthy people with high f1-
score (90%) in a non-invasive and privacy-friendly way based 
on only blood test samples. Such high classification perfor-
mance would greatly shrink the need for more advanced and 
screening procedures (e.g., mammograms), thereby reducing 
the medical costs on patients and governments. Offering con-
venient and highly accurate non-invasive diagnosis tools Fig.12. Simulation study results with the baseline approach 
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with the help of Metabolitics may greatly increase the number 
and frequency of screenings, as well as the rate of early diag-
nosis so that many lives may be saved before it gets late for 
treatment or intervention. 
In addition, Metabolitics is able to quantify the changes in 
pathways with no or small number of measurements in-
cluded in the metabolomics data set. This aspect makes Me-
tabolitics superior than the state of the art (e.g., Pathifier, Par-
adigm, etc.), as it leads to a larger coverage of the metabolic 
network. This strength of Metabolitics makes it robust to 
missing some of the key metabolites in the input metabolom-
ics data set, as demonstrated in our worst-case scenario-based 
robustness evaluation tests. The ability to provide insights 
even on the unmeasured parts of the metabolic network 
makes Metabolitics an invaluable tool for biochemistry, med-
icine, drug researchers in designing new therapies. 
 What is more, Metabolitics is not specific to metabolomics 
data. It may be employed for gene expression data analysis 
with a small modification. More specifically, the objective 
function of the dynamically constructed linear programming 
model would be set based on reactions (through geneen-
zyme) relationship, rather than on metabolites. The rest of the 
workflow will be the same. Given the huge amount of availa-
ble gene expression data, Metabolitics may enable researchers 
to make high impact discoveries regarding different diseases. 
The major future impact of Metabolitics lies in the medical 
informatics domain. As an example, Metabolitics may be in-
corporated into novel medical computing tools that may be 
used to help physicians make treatment decisions in a person-
alized manner. For each breast cancer patient, a different ex-
isting enzyme inhibitor drug may work. The key point here is 
to find those vital enzymes that will render the above discov-
ered metabolic mechanisms of a cancer cell non-viable. Once 
those key enzymes are identified, intervening with their 
known inhibitor drugs (if exist) may be a treatment option to 
be considered by an oncologist along with other options. We 
will develop such a recommender tool as follows: Once met-
abolic mechanism models are identified by Metabolitics, we 
will choose enzymes that are highly connected at high-flux 
regions of the network. We will remove those enzymes one 
by one, and apply Metabolitics on the remaining metabolic 
network to see if any feasible solution will be produced. Those 
enzymes, removal of which makes the metabolic network 
profile more similar to healthy people than people with the 
disease will be suggested as candidates for intervention with 
inhibitor drugs. For enzyme-inhibitor drug information, pub-
licly available sources, e.g. DrugBank [32], may be employed. 
There are already efforts in this direction (e.g., [70]), and we 
plan to extend these approaches by incorporating the pre-
built machine learning models into the analysis. 
Moreover, with a similar approach to the above-described 
one, Metabolitics may be used to develop in-silico experi-
mental models for drug design. That is, each enzyme (or a set 
of enzymes) may be considered as a possible drug target can-
didate. Then, Metabolitics is run with the constraint that the 
targeted region of the network will have no or minimal flux. 
Next, the analysis results are compared to the original analy-
sis results (before perturbation). If the new analysis results are 
classified as belonging to a healthy person by the pre-built 
machine learning model(s), then the targeted enzyme(s) may 
be considered as a promising drug candidate to be focused in 
clinical studies. 
Last but not the least, the proposed approach may also be 
employed in “intra-patient” studies. That is, metabolite con-
centrations from healthy and tumor tissues may be analyzed 
and compared to reveal the metabolic differentiation of tis-
sues from the same person. This way, person-to-person met-
abolic differences may be eliminated from the consideration, 
and health vs. disease state differentiation may be studied 
with minimal noise. 
We note the following limitations of our study. First, the 
provided diff values may not be directly validated with wet-
lab studies, as it is very difficult to quantify the actual flux 
change in eukaryotic cells in vivo. Second, we associate blood-
level measurements to the metabolic network chances in pa-
tient cells. However, the measured metabolite changes may 
be also resulting from the body’s response to the existence of 
a tumor in an individual. Hence, the reported metabolic 
changes may not be directly associated with the tumor cells. 
Thus, we use a more general scope as “patient cells” which 
may belong to healthy or tumor tissues. Nevertheless, Ganti 
et al. [16] compared simultaneous metabolomics measure-
ments from tumor tissue, blood, and urine, and show that 
blood is a “decent proxy for the tumor metabolism”. Many 
others (e.g., [21], [37], etc.) also suggested that blood metabo-
lite levels are associated with that of tumor tissues.  Finally, 
the coverage of the human metabolic network by the meas-
ured metabolites is still low, which leads to large upper-lower 
flux boundary intervals possibly obscuring some of the meta-
bolic changes taking place in patient cells. 
5 CONCLUSION 
Metabolic networks in patients often experience dramatic 
perturbations in comparison to healthy individuals. These 
perturbations carry important information regarding the root 
cause of the underlying condition. Hence, characterizing such 
changes is invaluable to (i) accurately diagnose patients, and 
(ii) prescribe a personalized treatment strategy. In this paper, 
we present Metabolitics algorithm. Given some metabolom-
ics measurements of an individual and a database containing 
metabolic network data, Metabolitics computes the metabolic 
network configuration that may lead to the measured 
changes in the provided metabolomics data. More specifi-
cally, it computes a personalized “diff” score for each path-
way that represents the amount and direction of activity 
change in the pathway of that individual. Our approach is 
based on dynamically creating a linear programming model 
of the metabolic network according to the given metabolite 
measurements, and performing a customized flux variability 
analysis on these models to quantify the differentiation of 
pathways in reference to healthy people. After computing diff 
scores, we built classification models which employ the com-
puted diff scores as features to differentiate patients from 
healthy individuals. We extensively evaluated Metabolitics 
on three different disease datasets, namely, breast cancer, 
Crohn's disease, colorectal cancer, and show that it can iden-
tify patients with around 90% accuracy (f1-score), and it pro-
vides biologically relevant metabolic analysis of diseases.  
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